扶正消癌方治疗乳腺癌术后内分泌综合征50例

孙献甫; 刘慧; 贺亚宁; 刘朝俊; 崔树德

doi:10.11653/syfj2014020192

您当前的位置：

首页 >

文章列表页 >

扶正消癌方治疗乳腺癌术后内分泌综合征50例

更新时间：2024-01-04

- 扶正消癌方治疗乳腺癌术后内分泌综合征50例
- Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation
- 中国实验方剂学杂志 2014年20卷第2期页码：192-195
- 作者机构：
- 作者简介：
- 基金信息：
  
  河南省重点科技攻关计划项目（122102310535）
- DOI：10.11653/syfj2014020192
  中图分类号：
- 纸质出版日期：2014
- 稿件说明：
移动端阅览
孙献甫, 刘慧, 贺亚宁, 等. 扶正消癌方治疗乳腺癌术后内分泌综合征50例[J]. 中国实验方剂学杂志, 2014,20(2):192-195.

SUN Xian-fu, LIU Hui, HE Ya-ning, et al. Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(2): 192-195.
孙献甫, 刘慧, 贺亚宁, 等. 扶正消癌方治疗乳腺癌术后内分泌综合征50例[J]. 中国实验方剂学杂志, 2014,20(2):192-195. DOI： 10.11653/syfj2014020192.

SUN Xian-fu, LIU Hui, HE Ya-ning, et al. Fuzheng Xiaoai Decoction 50 Cases of Syndrome Endocrine Treatment of Breast Cancer After Operation[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(2): 192-195. DOI： 10.11653/syfj2014020192.

摘要

目的：观察扶正消癌方对他莫昔芬（TAM）所致乳腺癌内分泌综合征的疗效及对乳腺癌患者生存质量的影响。方法：将100例患者随机按数字表法分为对照组和观察组各50例。对照组服用他莫昔芬（TAM），20 mg/次，1次/d，口服。观察组在对照组治疗的基础上加服扶正消癌方，1剂/d，连续服用2个月，症状改善后改为隔日1剂，再用2个月。并对所有患者随访3个月。采用改良Kupperman评分法评估临床主要症状积分；采用乳腺癌专用生存质量量表FACT-B（4.0）评价生存质量；记录治疗期和随访期内持续接受TAM治疗的例数。结果：治疗后观察组改良Kupperman评分明显下降（P<0.01），并低于对照组（P<0.01）；观察组症状积分改善率为80.0%优于对照组的12.0%（P<0.01）；治疗后观察组疾病控制率（DCR）为88.0%，优于对照组的72.0%（P<0.05）；观察组生存质量量表中生理状况和情感情况2个维度评分、特异条目评分及总分均较治疗前明显提高（P<0.01），并高于对照组（P<0.01）；观察组有6例（2.0%）无法坚持TAM治疗，低于对照组的19例（38.0%）（P<0.05）。结论：扶正消癌方能减轻乳腺癌内分泌综合征症状，提高患者TAM治疗依丛性，还能提高患者生存质量，使患者从中获益，值得临床使用。

Abstract

Objective: The purpose is to observe the curative effect of Fuzheng Xiaoai decoction in treatment of the breast cancer endocrine syndrome caused by tamoxifen (TAM) and its influence of life quality of breast cancer patients. Method: One hundred cases of patients were randomly divided into control group (50 cases) and observation group (50 cases) according to digital method. The patients in the control group took TAM

20 mg/time

1 time/day

orally. Based on the control group

patients in observation group took Fuzheng Xiaoai decoction additionally

1 dose/day

continued for 2 months. If the symptoms are improved

the frequency is changed to 1 dose every two days

continued 2 months. All the patients were followed up for 3 months. The modified Kupperman score method is used to evaluate the clinical main symptoms integral. The quality of life of patients with breast cancer-scale Functional Assessment of Cancer Therapy-Breast(FACT-B) (4.0) is used to evaluate quality of life

record the treatment and follow-up treatment cases during the continued TAM treatment period. Result: After the treatment

the modified Kupperman score of observation group significantly decreased(P<0.01) and was lower than the control group (P<0.01). The symptoms integral period of observation group was 80.0%

which is better than 12.0% of control group (P<0.01). Disease control rates (DCR) of observation group was 88.0%

which is better than 72.0% of control group (P<0.05). The physiological condition and emotional dimension score in the quality of life scale

specific entry score and total score of observation group were significantly improved (P<0.01) and were higher than the control group (P<0.01). There are 6 cases (2.0%) in observation group cannot keep TAM treatment

which is lower than 19 cases (38.0%) of control group (P<0.05). Conclusion: Fuzheng Xiaoai decoction can reduce breast cancer endocrine syndrome symptoms

improve compliance of patient in TAM treatment and improve the life quality of patients. It can make patients benefit and be worthy of clinical use.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

扶正疏肝消癌方对乳腺癌术后放化疗患者复发转移和生存质量的影响

基于巨噬细胞吞噬功能探讨六味地黄丸、二至丸、左归丸预防乳腺癌发生的机制

经典名方阳和汤的抗乳腺癌活性成分筛选

中药调控Wnt/β-catenin信号通路干预乳腺癌的研究进展

葫芦素B诱导细胞铁死亡抑制乳腺癌4T1细胞增殖作用及机制